# Immunoglobulin G4-related disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/immunoglobulin-g4-related-disease

> 2 upcoming FDA catalysts in immunoglobulin G4-related disease: Wayrilz (rilzabrutinib, SNY) on Jun to Sep 2028 (topline data readout); Wayrilz (rilzabrutinib, SNY) on June 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2024 | [UPLIZNA® (inebilizumab) topline data readout](https://sec-api.dev/pdufa/inebilizumab) | AMGN | Immunoglobulin G4-related disease | completed, positive | "In June 2024, we announced positive top-line results from our Phase 3 registrational trial evaluating UPLIZNA for the treatment of Immunoglobulin G4-related disease (IgG4-RD)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/amgn-20241231.htm)) |
| Apr 2025 | [UPLIZNA® (inebilizumab) FDA approval](https://sec-api.dev/pdufa/inebilizumab) | AMGN | Immunoglobulin G4-related disease | completed, approved | "In April 2025, we announced the FDA approved UPLIZNA for the treatment of Immunoglobulin G4-related disease (IgG4-RD) in adult patients." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm)) |
| Jun to Sep 2028 | [Wayrilz (rilzabrutinib) topline data readout](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Immunoglobulin G4 Related Disease | scheduled | "NCT07190196 (A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07190196)) |
| June 2028 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Immunoglobulin G4 Related Disease | scheduled | "NCT07190196 (A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07190196)) |

## Drugs

- [UPLIZNA® (inebilizumab)](https://sec-api.dev/pdufa/inebilizumab) (AMGN)
- [Wayrilz (rilzabrutinib)](https://sec-api.dev/pdufa/rilzabrutinib) (SNY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/immunoglobulin-g4-related-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Immunoglobulin G4-related disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/immunoglobulin-g4-related-disease

```bibtex
@misc{secapidev_indications_immunoglobulin_g4_related_disease_20261116,
  title        = {Immunoglobulin G4-related disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/immunoglobulin-g4-related-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_immunoglobulin_g4_related_disease_20261116","title":"Immunoglobulin G4-related disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/immunoglobulin-g4-related-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
